Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
Expect Eli Lilly's momentum to continue, says Bank of America's Geoff Meacham
02:40pm, Thursday, 02'nd Nov 2023
Geoff Meacham, Bank of America senior pharmaceutical analyst, joins 'The Exchange' to discuss Eli Lilly's performance, the demand outlook for weight loss drugs, and more.
Novo Nordisk, Lilly see insatiable demand for weight-loss drugs
01:16pm, Thursday, 02'nd Nov 2023
Novo Nordisk and Eli Lilly both expect juggernaut sales for their diabetes and weight-loss drugs to extend into coming years - limited only by their availability.
Compared to Estimates, Lilly (LLY) Q3 Earnings: A Look at Key Metrics
12:02pm, Thursday, 02'nd Nov 2023
While the top- and bottom-line numbers for Lilly (LLY) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare
Novo Nordisk, Eli Lilly stocks see boost on obesity drugs
11:26am, Thursday, 02'nd Nov 2023
Novo Nordisk (NVO) shares rose as the drugmaker's third-quarter profits jumped 56% year-over-year, fueled by surging demand for its obesity drugs Ozempic and Wegovy. Eli Lilly (LLY) shares also saw ga
Why Eli Lilly Stock Is Jumping Today
10:59am, Thursday, 02'nd Nov 2023
Lilly's Q3 revenue soared, but its earnings sank. However, the company's top- and bottom-line results handily beat Wall Street estimates.
Eli Lilly sees strong 3Q sales fueled by Mounjaro but cuts profit outlook
10:56am, Thursday, 02'nd Nov 2023
Eli Lilly and Co (NYSE:LLY) reported impressive third-quarter revenue as its diabetes drug Mounjaro exceeded sales expectations. The blockbuster drug generated quarterly sales of $1.41 billion, markin
Eli Lilly results top estimates on Mounjaro strength but slashes full-year profit outlook
08:10am, Thursday, 02'nd Nov 2023
CNBC's Joe Kernen reports on the company's quarterly earnings results.
Eli Lilly Stock Falls as Earnings Guidance Slashed Dramatically
06:54am, Thursday, 02'nd Nov 2023
Lilly slashes its guidance for full-year earnings to a range of $6.50 to $6.70 a share, having raised its outlook in August to a range of $9.70 to $9.90.
Eli Lilly's stock drops after surprise profit is reported but full-year outlook was slashed
06:51am, Thursday, 02'nd Nov 2023
Shares of Eli Lilly & Co. LLY, +0.10% dropped 1.8% in premarket trading Thursday, after the drug giant reported a surprise third-quarter profit but slashed its full-year outlook, due primarily to acqu
7 A-Rated Tech Stocks to Buy for November
06:40am, Thursday, 02'nd Nov 2023
Last year wasn't the best year for tech stocks. Some of the biggest names on Wall Street stumbled through the year as companies that were flush with growth during the Covid-19 pandemic adjusted to lea
Eli Lilly beats quarterly revenue estimates on Mounjaro strength
06:36am, Thursday, 02'nd Nov 2023
Eli Lilly beat Wall Street's revenue estimates for the third quarter on Thursday, lifted by strong demand for its diabetes drug Mounjaro that brought in over a billion dollars in sales.
Weight-loss drug maker reports 56% profit surge, as it continues to limit supplies
04:34am, Thursday, 02'nd Nov 2023
Novo Nordisk said Thursday it's still struggling to meet demand for its wildly popular weight-loss medications as its third-quarter profit jumped.
Curious about Lilly (LLY) Q3 Performance? Explore Wall Street Estimates for Key Metrics
10:34am, Wednesday, 01'st Nov 2023
Evaluate the expected performance of Lilly (LLY) for the quarter ended September 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics f
Investor patience tested as pharmaceutical stocks take a tumble
06:07am, Wednesday, 01'st Nov 2023
The Health Care Select Sector SPDR Fund NYSEARCA: XLV was down 3.81% in the past month and 8.03% in the past three months. The latest round of pharmaceutical stock earnings isn't helping sector perfor
Why Beam and Verve Therapeutics Shares Soared While Eli Lilly Soured Today
07:09pm, Tuesday, 31'st Oct 2023
The trio was involved in a deal for gene-editing programs. The arrangement is potentially worth $600 million.
